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Abstract Mucopolysaccharidoses (MPSs) are a group of ly-
sosomal storage disorders (LSDs). The increasing interest in
newborn screening procedures for LSDs underlines the need
for alternative cellular and gene therapy approaches to be de-
veloped during the perinatal period, supporting the treatment
of MPS patients before the onset of clinical signs and symp-
toms. The rationale for considering these early therapies re-
sults from the clinical experience in the treatment ofMPSs and
other genetic disorders. The normal or gene-corrected hema-
topoiesis transplanted in patients can produce the missing pro-
tein at levels sufficient to improve and/or halt the disease-
related abnormalities. However, these current therapies are
only partially successful, probably due to the limited efficacy
of the protein provided through the hematopoiesis. An alter-
native explanation is that the time at which the cellular or gene
therapy procedures are performed could be too late to prevent
pre-existing or progressive organ damage. Considering these
aspects, in the last several years, novel cellular and gene ther-
apy approaches have been tested in different animal models at
birth, a highly early stage, showing that precocious treatment
is critical to prevent long-term pathological consequences.
This review provides insights into the state-of-art accomplish-
ments made with neonatal cellular and gene-based therapies
and the major barriers that need to be overcome before they
can be implemented in the medical community.
Introduction
Background
Mucopolysaccharidoses (MPSs) comprise a group of lyso-
somal storage disorders (LSDs) having in common the
inherited deficiency of a particular lysosomal enzyme and
the subsequent accumulation of undigested glycosaminogly-
cans (GAGs). GAG storage results in loss of cellular func-
tions, tissue damage, and organ dysfunction accounting for
clinical signs and symptoms observed in patients. Clinical
manifestations include mental retardation, skeletal dysplasia,
corneal clouding, abnormal facies, coarse hair, hernia,
hepatosplenomegaly, respiratory and valvular heart diseases,
and abnormal joint mobility (Neufeld and Muenzer 2001). At
the skeletal level, MPS patients develop a characteristic
dysostosis multiplex due to the progressive storage of GAGs
in the bones, especially chondroitin sulfate, dermatan sulfate,
and/or keratan sulfate (Neufeld and Muenzer 2001).
Difficulty in early diagnosis
It is extremely difficult to diagnose MPS patients at birth, and
even at the onset of clinical disease. For instance, most MPS I
patients may not have MPS-specific signs and symptoms at
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birth although umbilical and/or inguinal hernia is common.
Diagnosis of Hurler syndrome, the most severe form of
MPS I, is commonly made between 4 and 18 months of age.
A combination of symptoms, as skeletal deformities, recurrent
respiratory infections, inguinal and umbilical hernias, coarse
facial features, hepatosplenomegaly, and enlarged tongue
leads to initial medical attention. Without appropriate treat-
ment, the life expectancy of patients with Hurler syndrome
is limited: the median survival is less than 10 years, with only
rare survivors beyond 10 years. Diagnosis of other types of
MPS may be delayed more than MPS I since clinical mani-
festations occur later.
Early treatments
Currently, several treatments such as enzyme replacement
therapy (ERT), hematopoietic stem cell transplantation
(HSCT), and gene therapy are being evaluated for MPSs.
ERT and HSCT are clinically available, and gene therapy is
under clinical trials for some types of MPSs. ERT, based on
the administration of recombinant enzyme, is actually being
employed in patients with MPS I (Kakkis et al 2001), MPS II
(Muenzer et al 2002, 2006), MPS IVA (Hendriksz et al 2014),
MPS VI (Harmatz et al 2008), and MPS VII (Fox et al 2015).
Indeed, the treatment with ERT has shown demonstrable ben-
efits, especially in joint mobility, respiratory functions, decre-
ment in organs volumes, and reduction in urinary GAG excre-
tion (Muenzer 2014). However, current ERT for MPSs has
severe limitations, such as an inadequate effect on skeletal
and neurological symptoms (Connock et al 2006; Muenzer
2014; Rohrbach and Clarke 2007), a rapid clearance from
the circulation, and immune reactions, due to the development
of anti-enzyme antibodies (Dickson et al 2008; Kakkis et al
2001). Several demonstrations have shown that the earlier
ERT is performed in animal models and human patients, the
better the outcome is (Dierenfeld et al 2010; Sands et al 1994;
Tomatsu et al 2015). Similar evidence comes from the follow-
up analysis of MPS I patients treated with HSCT. Indeed, a
retrospective analysis could demonstrate superior long-term
clinical outcome for patients with MPS I when HSCT was
performed early in life (Aldenhoven et al 2015; Boelens et al
2013). HSCT of MPS I patients (transplanted with a median
age of 16 months) improves their quality of life and
neurocognitive development, albeit the therapeutic effect on
bone lesions remains limited (Aldenhoven et al 2015; Boelens
et al 2013). The musculoskeletal manifestations are still dete-
riorated and provide an impact on the quality of life in most
transplanted patients with MPSs (Aldenhoven et al 2008).
One explanation could be the limited penetration of the
expressed enzyme into musculoskeletal tissues (Field et al
1994). Another possibility is that irreversible bone damage
has already occurred prior to the time of the transplant. Con-
sidering the current experimental and clinical data on both the
available treatment options, it is likely that an early interven-
tion in patients with MPSs could be critical for obtaining a
higher degree of correction. It is notable that MPSs may rep-
resent the ideal model for elucidating these aspects since 1)
they are monogenic diseases, 2) several animal models are
available, and 3) the successful restoration of even a low level
of enzyme activity is expected to be sufficient to correct or
improve the disease. For these reasons, MPSs are conceived
as conditions suitable for the evaluation of innovative early
therapeutic strategies.
In particular, this review focuses on the scientific evidence
demonstrating that cellular and gene therapies in the neonatal
period provide a real therapeutic perspective for MPS
disorders.
Neonatal hematopoietic stem cell transplantation
Cellular therapy is relevant for some forms of MPSs. HSCT
has been shown to be one of the most effective treatment
strategies for patients with Hurler syndrome. In particular,
the use of various HLA-matched hematopoietic stem cell
sources (peripheral blood, bone marrow of unrelated donors
or cord blood) has contributed to offer a transplantation strat-
egy to a significant number of patients (Aldenhoven et al
2008; Peters et al 2003; Rovelli 2008; Yasuda et al 2015).
In general, early HSCT improves the pathology in all or-
gans although bone lesions have a lesser impact compared
with visceral organs. Thus, HSCT alleviates most clinical
manifestations in these patients, probably due to the migration
of the transplant-derived cells into organs, where they can
secrete the functional enzyme and clear the lysosomal storage
leading to the correction of the metabolic defect. However, the
effect of HSCT on the orthopedic manifestations is limited
likely by the poor penetration of the donor cells into the mus-
culoskeletal tissues (Aldenhoven et al 2008; Field et al 1994).
It is likely that HSCT provides more circulating enzyme to
bone rather than directly affecting bone by migration of the
cells.
Furthermore, the recovery of the patients’ skeletal pheno-
type produced by HSCT could be incomplete likely because
bone abnormalities are irreversible at the time of the trans-
plant. For this reason, the impact of HSCT could still benefit
from further improvements, as the use of different stem cell
sources and/or alternative transplant procedures. In particular,
a neonatal cellular therapy approach may hold more promise,
considering that it would allow preventing the progressive
disease manifestations, which develop during early stage.
Several reports have evaluated if the perinatal infusion of
stem cells of hematopoietic origin could ameliorate the most
prominent clinical features in MPS animal models (Table 1).
Soper et al published a study describing a non-ablative neo-
natal marrow transplantation model in MPS VII mice (Soper
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et al 2001). Despite low-level engraftment of donor cells,
MPSVII mice treated with bone marrow transplantation
(BMT) in neonatal life have shown several improvements,
including extension of life span, reduction of lysosomal stor-
age in multiple tissues, and amelioration of bone parameters
(Sands et al 1993; Soper et al 2001). Successive neonatal
BMT procedure in the MPS VII mice also proved that the
aberrant electrocardiogram and many of the progressive heart
lesions were corrected in the long-term (Schuldt et al 2004).
Furthermore, BMT in newborn MPS VII mice has led to the
prevention of early hearing loss and to an improvement in the
histopathology of the ear (Sands et al 1995). In the central
nervous system (CNS), a consistent reduction in the amount
of storage in the meninges and glial cells, but not in the neo-
cortex, hippocampus, and cerebellum has been reported
(Soper et al 2001). It is noteworthy that the CNS function of
MPS VII mice, transplanted after a myeloablative irradiation
and evaluated with two behavioral tests, was not ameliorated
in transplanted mice (Bastedo et al 1994). Similarly, in a
mouse model of MPS IIIA, neonatal BMT did not affect neu-
ropathological storage (Lau et al 2013). Likewise, BMT of
MPS IIIB mice performed at 2–4 days of age after irradiation
did not show any evident improvement in the brain
(Heldermon et al 2010). The authors concluded that BMT
does not correct the CNS abnormalities of transplanted mice,
even though the lack of improvement could also be attributed
to the transplant procedure, in particular to radiation-induced
toxicity in CNS or to the low engraftment of donor cells.
With the aim of evaluating the effect at the skeletal level,
neonatal BMT has recently been tested in a MPS I mouse
model (Pievani et al 2015). This study adopted a busulfan-
based conditioning followed by a syngeneic BMT in the first
days of life. Busulfan is a standard chemotherapy agent used
in patients in combination with other drugs as a conditioning
prior to HSCT, especially in leukemia, lymphoma, myelopro-
liferative disorders, and MPSs. The use of busulfan in a neo-
natal experimental setting is an element of interest since it
allows a better engraftment of donor cells in the brain com-
pared with irradiation, which could also provide an effect on
the neurological manifestations of the disease (Wilkinson et al
2013). Furthermore, by using this experimental regimen with
busulfan in MPS I mice (Pievani et al 2015), the extent of
engraftment obtained was high, and the successive clinical
improvement was very encouraging. The replacement of the
hematopoiesis resulted in an increase in alpha-L-iduronidase
(IDUA) activity in peripheral organs and, consequently, clear-
ance of GAGs in plasma and various tissues. At 37 weeks of
age, the reconstitution of normal hematopoiesis inMPS I mice
was associated with a consistent amelioration of skeletal dys-
plasia. Radiographic analysis showed that the widths of the
skull, of the zygomatic arches, and of the long bones in MPS I
early-treatedmice were almost normalized. The bonemorpho-
metric parameters calculated bymicro-CT revealed a 40–80%
improvement in neonatally transplanted compared with
untransplanted MPS I mice, approaching the values observed
in WT. The authors also noticed a reduction of both
hyperosteocytosis and lysosomal vacuolization in femur sec-
tions of neonatally transplanted MPS I mice.
Overall, the magnitude of improvements correlated with
the extent of hematopoietic engraftment, interestingly sug-
gesting that the early restoration of normal hematopoiesis pro-
vides a favorable impact on the bone development in MPS I.
Therefore, BMT at a very early stage in life reduces signs and
symptoms of MPSs in animal models by preventing their
development.
Neonatal gene therapy
Gene therapy also offers a potential therapeutic opportunity
for MPSs. In theory, gene therapy for these disorders should
act by providing the affected cells with enough enzyme. The
mechanisms by which gene therapy could be effective include
1) the delivery of the gene directly to the cells mainly involved
in these diseases and 2) the uptake by these cells of the missing
enzyme secreted from other transduced cells acting as an en-
zyme source. Early gene transfer in the neonatal period over-
comes some issues, which can occur in gene therapy per-
formed in adulthood. First, in mature organisms affected by
MPSs, the genetic defect has already caused irreversible path-
ological lesions mainly in bone and brain. Therefore, for
MPSs and many other genetic diseases, gene therapy at birth
will have a striking effect to arrest disease progression. In
addition, if gene therapy is administered in adulthood, an im-
mune response may rapidly eliminate transgenic protein ex-
pression precluding any favorable effect. In contrast, with an
early intervention, the possibility to develop a vigorous im-
mune system response toward the transgenic protein is less
likely than in adulthood. Furthermore, in the case of an ap-
proach based on the use of genetically corrected hematopoi-
etic stem cells, the autologous setting reduces the risks related
to an allogeneic transplant (graft versus host disease, GVHD)
and provides potential advantage to patients lacking an HLA-
matched donor.
In addition, a study in the MPS VII mouse model has
shown that, as the disease progresses, more genes present
altered expression, and this may account for the complex clin-
ical phenotype. Only some of those changes in gene expres-
sion normalize when the treatment is initiated in animals with
established disease, and this observation further supports the
need of an early intervention (Woloszynek et al 2004).
The two primary categories of somatic gene therapy consist
of (1) the in vivo infusion of viral vector particles with the aim
of transferring normal cDNA to the affected cells enabling
them to express the missing protein or (2) the ex vivo trans-
duction of patient’s cells which could be subsequently infused
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(Fig. 1). The first form of gene therapy is called in vivo be-
cause the gene vector is transduced to cells inside the patient’s
body. In the ex vivo procedure, cells from the patient’s blood
or bone marrow are cultured in the laboratory, exposed to the
viral vector that is carrying the desired gene and then returned
to the patient.
In vivo neonatal gene therapy
In the last two decades, in vivo gene therapy studies in neo-
natal MPS mice and large animal models have been reported
by using retroviral, adenoviral, lentiviral, and adeno-
associated virus (AAV)-based vectors (Table 1). Systemic
gene therapy could program some cells to secrete the lacking
enzyme, which could be taken up by other affected cells via
the mannose 6-phosphate receptor. The first report demon-
strating the several advantages of an early in vivo gene therapy
approach showed that intravenous AAV-mediated gene trans-
fer in neonatal MPS VII mice may offer an efficient system to
widespread correction (Daly et al 1999b). Also in a CNS-
directed gene therapy approach, the injection of recombinant
AAV encoding human GUSB into both the anterior cortex
than the hippocampus of newborn MPS VII mice had positive
effect not only on the brain histopathology, but also improved
cognitive function (Frisella et al 2001). Subsequently, Hartung
et al treated MPS I mice at birth with an AAV vector carrying
the human IDUA cDNA and showed that AAV-IDUA gene
transfer into newborn MPS I mice led to high levels of plasma
and tissue enzyme activities, which were sufficient to normal-
ize urine GAG levels and reduce lysosomal storage in a num-
ber of the main organs of treated mice (Hartung et al 2004).
The effect of IDUA restoration on craniofacial and CNS pa-
rameters demonstrated significant improvements on these crit-
ical features of MPS I. Similarly, the in vivo injection of high
doses of retroviral vector expressing IDUA resulted in the
complete correction of biochemical and pathological evidence
of disease in internal organs, bone, and brain (Chung et al
2007; Liu et al 2005). In particular, Liu et al showed that
MPS I mice that received high-dose of retroviral vectors had
normal echocardiograms, bone mineral density, auditory-
evoked brain-stem responses, and electroretinograms (Liu
et al 2005).
With the advent of lentivirus-based vector technology,
Kobayashi et al estimated the possibility to perform gene
therapy for MPS I by direct in vivo injection of a lentiviral
vector (Kobayashi et al 2005). They compared the efficacy
between newborn and young adult MPS I mice of lentiviral
vector-mediated gene therapy, demonstrating a significant-
ly greater advantage for mice treated neonatally. In particu-
lar, they showed that the neonatal administration of the
lentiviral vector by a single intravenous injection led to a
sustained expression of active IDUA enzyme in multiple
organs, including the brain, in which vector administration
resulted in transduction of neurons in the brain. Interesting-
ly, the authors were able to show a clear advantage in mice
treated as neonates compared to those treated as young
adults. Indeed, the disease manifestations were only moder-
ately improved in this latter group, but almost normalized in
mice treated earlier in life. When the vector was adminis-
tered at birth, the IDUA activity resulted in decreased GAGs
storage, prevention of skeletal abnormalities, a more normal
gross appearance, and improved survival. The extent of
transduction was dose-dependent, with the liver receiving
the higher level of the vector, but other somatic organs
reaching almost similar levels.
Fig. 1 Scheme of the approaches employed for the neonatal therapy of
MPS animal models. a Cell therapy. Cells from the bone marrow (or
alternative stem cell sources) of a healthy donor are collected and then
transplanted into the affected newborn. b Gene therapy in vivo. A viral
vector carrying a functional copy of the defective gene is injected into the
organism of the affected neonate. c Gene therapy ex vivo. Bone marrow
stem cells (or stem cells from other sources) are transduced ex vivo with a
viral vector carrying a copy of the defective gene and then gene-corrected
cells are transplanted into the affected neonate. Two important factors in
the experimental setting are the conditioning and the route of
administration. The effectiveness of the approach is evaluated, and the
outcome is observed focusing on biochemical and clinical parameters.
Abbreviation: TBI, total body irradiation; IV, intravenous; IP,
intraperitoneal; IM, intramuscular; CNS, central nervous system (route:
intraventricular or intratechal); GAGs, glycosaminoglycans
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All these works provided different confirmations of the
effectiveness of an early gene therapy approach on MPS
mouse models, independently of the type of vector used.
In recent years accumulating evidence has provided sup-
port for the hypothesis that another critical point, which can
impact the efficacy of the neonatal gene therapy approach, is
dependent not only on the virus type used but also on the route
of administration.
The intracranial injection alone of an adeno-associated vi-
ral (AAV) vector in the mouse model of MPS IIIB resulted in
improvement in lifespan, motor function, hearing, time to ac-
tivity onset, and daytime activity level, but no effects on the
lysosomal storage (Heldermon et al 2010). A more recent
report has described a novel approach using the combination
of an intracranial injection of an AAV-based vector and an
intravenous treatment with a lentiviral vector, showing better
clinical, histological, and biochemical features (Heldermon
et al 2013).
Although the majority of gene transfer experiments for the
treatment of inherited or acquired diseases have mainly been
performed in mice, large animal models clearly represent an
important step in the preclinical evaluation of a gene therapy
approach, as their responses are probably more predictive of
the results in humans. Large animals are more similar in size
to a neonate offering a more sophisticated disease modeling
resembling several human features.
The efficacy of neonatal gene therapy has also been tested
in large MPS animal models. The first successful application
of neonatal gene therapy in large animals has been described
by Ponder et al, who reported the clinical improvements seen
in MPS VII dogs treated with a cGUSB-expressing retroviral
vector as neonates (Ponder et al 2002). In particular, little or no
corneal clouding and no mitral valve thickening have been
observed. Radiographically, treated dogs had fewer skeletal
abnormalities, and, therefore, they could run at all planned
times of evaluation. Estimating the long-term effect of this
treatment on MPS VII dogs, the authors concluded that neo-
natal gene therapy was able to appreciably, even if not entirely,
reduce bone and joint disease (Xing et al 2013). It is notable
that neonatal gene therapy in MPS VII dogs was still not effec-
tive in preventing lumbar spine disease (Smith et al 2012).
Similarly, in newborn MPS VI cats treated with a feline N-
acetylgalactosamine 4-sulfatase-expressing retroviral vector,
the results indicated, at the bone level, improvements in some
aspects such as femur length, articular cartilage erosion, mobil-
ity, but not a significant effect on cervical vertebral bone length
(Ponder et al 2012). Thus, the impact of neonatal gene therapy
is different in different bones. It is of great interest to understand
which bone is severely affected, when each bone starts to be
affected by the disease or what difference is present in penetra-
tion of gene vector and its expression level in each bone.
Pivotal information can be evinced from the studies con-
ducted in MPS I dogs (Traas et al 2007). In this work, MPS I
dogs were treated at birth with a gamma retroviral vector ex-
pressing the canine IDUA, and yielded a clinical effect de-
rived from a stably expressed and circulating enzyme without
showing an immune response (Traas et al 2007). The authors
speculated that the immaturity of the newborn immune system
or the tolerance to canine IDUA epitopes could have contrib-
uted to prevent the production of anti-canine IDUA
antibodies.
These findings on neonatal in vivo gene therapy are prom-
ising and pave the way for upcoming clinical trials, even if
future studies in patients need to assess the risks and benefits
of the adopted vector.
Ex vivo neonatal gene therapy
Ex vivo gene therapy consists of two steps: 1) infecting so-
matic cells in vitro by viral vectors, then 2) injecting gene-
corrected cells in vivo into a newborn recipient organism.
Such an approach is of particular interest in the case of MPSs:
in fact, it allows the transduction of the defective gene directly
into recipient cells, and the subsequent transplant of trans-
duced cells in an autologous setting, avoiding the common
immune issues of allogeneic transplantation. Moreover, the
viral infection often allows reaching supraphysiological levels
of protein expression in corrected cells, which could never be
achieved using normal donor cells as a source of enzyme. This
is another apparent advantage of ex vivo gene therapy, since it
has been shown in animal models and in clinic that the extent
of phenotypic correction is strongly related to the levels of
enzyme activity reached in the recipient organism (organs or
biological fluids) as a result of the treatment (Aldenhoven et al
2015; Visigalli et al 2010).
In MPS animal models, this gene-correction strategy has
mainly been performed on long-term hematopoietic
repopulating cells, usually derived from bone marrow, which
are cultured and transduced, and then transplanted into recip-
ients with a standard procedure of bone marrow transplanta-
tion (Visigalli et al 2010; Wakabayashi et al 2015; Wang et al
2009; Zheng et al 2003).
Only a few papers related to neonatal ex vivo gene therapy
inMPS animals have been published (Table 1). Simonaro et al
described the transplantation of retrovirally transduced bone
marrow (BM) or newborn blood cells inMPSVI cats, some of
which were very early in life. Cells transduced with the vector
carrying the cDNA for the human arylsulfatase B, the enzyme
deficient in MPS VI, were successfully engrafted and
persisted for a long term in the cats, while the level of enzyme
activity reached was low, not sufficient to appreciate any clin-
ical improvement. Notably, the authors employed as cell
source not only BM, but also newborn blood, in an attempt
to verify the feasibility of transplanting gene-corrected cord
blood (Simonaro et al 1999).
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Other cell types have also been employed for gene correc-
tion. In 2003, Meng et al focused on the CNS involvement in
MPSs. They transduced human neural stem cells (hNSCs)
with a retroviral vector, in order to express the human enzyme
ß-glucuronidase at supranormal levels; then they injected
corrected cells into the cerebral ventricles of immunodeficient
MPS VII newborn mice. They identified the presence of
hNSCs in host brains, the presence of ß-glucuronidase activ-
ity, and a reduction of lysosomal storage. Unfortunately, these
effects lasted only for a short time after transplantation be-
cause human cells rapidly underwent apoptosis (Meng et al
2003).
Meyerrose et al obtained even more encouraging results.
They transduced human BM-derived mesenchymal stem cells
(hBM-MSCs) by a lentiviral vector, forcing them to overex-
press human ß-glucuronidase. The intraperitoneal transplanta-
tion of corrected hBM-MSCs into neonatal NOD-SCID MPS
VII mice leads to the engraftment of these cells in several
organs and to their release of therapeutic levels of enzyme
(nearly 40 % of normal in serum), detected 2 and 4 months
after the transplant. As a result, the storage of GAGs and the
secondary elevated activities of other lysosomal enzymes
were normalized. Notably, the authors attested even a clinical
amelioration since treated mice showed an improvement in
retinal function (Meyerrose et al 2008).
The described approaches, with their interesting initial re-
sults, are significant proofs of principle for the application of
ex vivo gene therapy in the very early treatment of MPSs.
Advent of newborn screening programs and future
neonatal therapies
Newborn screening on MPSs
It is inevitable to establish newborn screening systems for
MPS patients to allow an early diagnosis and early therapy.
There are two principal methods that are being developed and
pilot studies are currently underway; one is the assay which
measures the deficient enzyme in each MPS disorder, and the
other one is the assay which measures primary storage sub-
strates, GAGs. Both methods will analyze newborn dried
blood spots (DBSs).
Enzyme assay method can be a useful tool in newborn
screening for MPSs, measuring the activity of each deficient
enzyme directly. This method is highly sensitive and specific.
There are several reports of enzyme assays in MPS I
(Blanchard et al 2008; Wang et al 2005) and MPS II (Wang
et al 2007) patients. This group and others have developed
direct multiple assays of enzyme activity in DBS samples by
using tandem mass spectrometry (MS/MS) for newborn
screening of lysosomal storage diseases (Gelb et al 2006; Li
et al 2004). The enzyme assay can provide a diagnosis of the
disease directly while the disadvantage is that the method
cannot differentiate the pseudodeficiency from true positive
patients. The micro-fluidics methodology is also being inves-
tigated for screening DBSs and has already been applied in a
full-population pilot study in Missouri (Hopkins et al 2015).
Another method is to measure primary storage materials,
GAGs. Several groups have developed highly sensitive, spe-
cific, and inexpensive assay methods to distinguish patients
with MPSs from healthy controls by using liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
systems. Tomatsu et al measured heparan sulfate and
dermatan sulfate levels in DBS samples from six neonatal
MPS patients (four MPS I, one MPS II, and one MPS VII)
and compared each GAG level from these MPS samples with
that from healthy control samples (n=326) in a double blind
method. Both levels were markedly elevated in all six samples
of MPS patients compared with the levels of control samples
(Oguma et al 2007; Tomatsu et al 2010a, b, c). This group also
measured 12 newborn samples with MPSs (six MPS I, one
MPS II, and five MPS III) using both LC-MS/MS and high-
throughput mass spectrometry (HT-MS/MS) (Shimada et al
2014). The disaccharide levels of ΔDiHS-0S and ΔDiHS-
NS from DBS samples with MPS I or MPS III were markedly
elevated compared with those from control newborn samples
(n=22). Also in the case of MPS II samples, these levels were
respectively 3 and 1.5 times higher than in controls (Shimada
et al 2014). De Ruijter et al have also reported that the disac-
charide levels of heparan sulfate and dermatan sulfate from
newborn DBS samples obtained from MPS patients (11 MPS
I, oneMPS II, and sixMPS III) were significantly increased in
all patients samples compared with controls (de Ruijter et al
2012).
Therefore, these methods of newborn screening for MPS
patients can be useful tools to make an early diagnosis for at
least MPS I, II, and III. This group is starting a pilot study to
measure specific GAGs from a total of 200,000 newborn DBS
samples and to evaluate the new assay systems for MPSs
newborn screening. This method provides a suggestion of a
high-risk group for MPSs and can be useful for assessing the
clinical severity of the disease and monitoring the therapeutic
efficacy and/or pharmacokinetics of the drug, while the sec-
ond screening with enzyme assay is required for certain
diagnosis.
Both methods have some limitations, such as false-posi-
tive/negative and costs in GAG assay and enzyme assay meth-
od. These issues still need to be resolved before establishing a
newborn screening system for MPSs in the clinical practice.
Future neonatal therapies
As previously mentioned, ERT is a standard therapy for MPSs
and is approved or under clinical trials in many countries for
MPS I, MPS II, MPS IVA, MPS VI, and MPS VII patients.
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Patients treated with ERT showed clinical improvement of
somatic manifestations and an enhanced quality of life. How-
ever, there are several limitations: 1) ERT is least efficacious
on CNS and skeletal dysplasia, 2) the enzyme has a short half-
life and high clearance from the circulation, 3) continuous
ERT causes immunological problems, and 4) it is very
expensive.
HSCT for MPS patients has been conducted prior to ERT;
however, initial attempts of HSCTwere controversial because
of a highmortality rate. Several results onMPS animal models
suggest that skeletal deformities and impaired growth devel-
opment in MPS patients should be improved if HSCT is per-
formed at earlier stages. HSCT has a risk for the development
of mortality by GVHD, infections and additional complica-
tions. It is known that the severity of GVHD is influenced by
the donor match and by pre-HSCTserotherapy. Anyway, con-
ditioning regimens for HSCT have been markedly improved
in each medical facility, and well-trained staffs contribute to
the least mortality of HSCT.
Busulfan is a standard chemotherapy drug usually given as
a conditioning agent prior to HSCT. However, this drug may
still induce severe side effects such as toxicity in lung and
liver. Treosulfan (treo) is another alkylating cytotoxic agent
with a supposedly less severe toxicity profile. It is most com-
monly used in the treatment of ovarian cancer. It is also in-
creasingly used in HSCT, predominantly in non-malignant
diseases. In European countries, treosulfan is approved and
used efficiently and safely in pediatric patients before HSCT
(Bernardo et al 2012; Boztug et al 2015; Slatter et al 2011;
Strocchio et al 2015; Wachowiak et al 2011). Pediatric MPS
patients, who received a conditioning regimen consisting of
treosulfan and others, achieved stable hematopoietic engraft-
ment and stable donor chimerism without GVHD. The regi-
men with treosulfan could be an additional option when un-
related donor HSCT is considered for a patient with MPS
(Schwinger et al 2014) although the donor cell engraftment
into the brain might be limited with this type of transplant. The
long-term observation of HSCT with treosulfan is required.
Neonatal or early HSCT can be more widely spread as the
main therapy for patients with MPS if treosulfan regimen is
established in each type of MPS.
It should be noted that, to date, cord blood is a clinically
useful source of HSCT for Hurler syndrome. Full-donor chi-
merism and normal enzyme levels are frequently achieved
during the follow-up period (Boelens et al 2013; Staba et al
2004). Cord blood transplantation also improves
neurocognitive development in children with Hurler syn-
drome (Staba et al 2004). In general, HSCT with cord blood
has many advantages such as 1) easy procurement, 2) no risk
to donors, 3) low risk of transmitting infections, 4) immune
tolerance allowing successful transplantation despite HLA
disparity, and 5) immediate availability (Aldenhoven and
Kurtzberg 2015; Wagner et al 2009). The latter is clearly suit-
able for performing an early therapy. It is still critical to assess
whether HSCT with cord blood might provide significant
GVHD or not with more cases.
For what concerns neonatal gene therapy, animal studies on
MPSs suggest that the viral and non-viral vectors have stably
overexpressed within a long period of 10 years. In ex vivo
gene therapy, retroviral vectors improved CNS disease in
Fig. 2 Gene editing-based
therapy in human albumin locus.
1. Gene editing-based therapy for
MPS I or II patients targets
albumin locus sites in the liver. 2.
ZFN binds to DNA sequences in
the albumin locus and their fok1
nuclease domains dimerize
between the binding sites. 3. ZFN
induces DSB at the albumin locus
in the genome of hepatocytes. 4.
Alpha-L-iduronidase or
iduronate-2-sulfatase genes are
inserted into the albumin locus,
and their proteins are continually
produced from the liver into the
blood. Abbreviation: ZFN, zinc
finger nucleases; DSB,
double-strand breaks
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MPS I (Zheng et al 2003) and MPS IIIB (Zheng et al 2004)
mice. Direct infusion of viral vectors into the brain also im-
proved CNS disease by in vivo gene therapy (Berges et al
2006; Bosch et al 2000; Ciron et al 2006; Desmaris et al
2004; Ghodsi et al 1998). However, the efficacy of gene ther-
apy for bone lesions remains unsolved. Several clinical trials
in gene therapies for MPSs are currently underway in the
United States. Phases I and II clinical studies for the therapy
of Sanfilippo A syndrome using adeno-associated viral vector
serotype rh. 10 carrying the human N-sulfoglycosamine
sulfohydrolase (SGSH) and sulfatase-modifying factor
(SUMF1) cDNAs are still ongoing (Tardieu et al 2014).
The future ideal gene therapy practice is that the defective
gene is replaced with a normal sequence at its natural location.
This is advantageous compared with a virally delivered gene
which includes the full coding and regulatory sequences when
only a small proportion of the gene is required to be changed,
like a point mutation or small deletion and insertion. The
expression of the partially replaced gene can be more consis-
tent with normal cell physiology than the full gene accommo-
dated by the viral vector.
Gene editing, or gene editing with engineered nucleases, is
a type of genetic engineering representing an innovative tech-
nology. Through this system, a DNA fragment of interest is
inserted, replaced, or removed from a genome by using artifi-
cially engineered nucleases or Bmolecular scissors^. The nu-
cleases generate specific double-strand breaks (DSB) at pre-
ferred sites in the genome and employ the endogenous mech-
anisms of homologous recombination and nonhomologous
end-joining to restore the induced break point. At present, four
families of engineered nucleases are in use experimentally or
in clinical trials: zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), the CRISPR/Cas
system (CRISPR: clustered regularly interspaced short
palindromic repeats; Cas: CRISPR-associated genes), and
engineered meganuclease and re-engineered homing endonu-
cleases (Esvelt and Wang 2013; Puchta and Fauser 2014; Tan
et al 2012) (Fig. 2).
For example, ZFN-induced targeting attacks defective
genes at their endogenous chromosomal locations. Treatment
of X-linked severe combined immunodeficiency has been ad-
ministered by ex vivo gene correction with DNA carrying the
IL-2 receptor common γ chain with the correct sequence
(Lombardo et al 2007). However, one of the concerns about
this new technology is that ZFNs may induce off-target mu-
tations, apart from viral transductions. Many measures are
under development to improve off-target detection and ensure
safety prior to clinical use.
A particular use of gene editing is the in vivo protein re-
placement platform (IVPRP), which provides a broadly appli-
cable genetic approach to enzyme replacement for LSDs
(DeKelver et al 2015). The IVPRP applies ZFN-mediated
gene editing to insert precisely normal genes into the albumin
locus of liver cells in patients (Fig. 2). Successively, the nor-
mal enzyme is produced by the robust device that naturally
drives albumin expression, leading to the production and se-
cretion of the defective enzyme by the liver. At this moment,
Hurler syndrome and Hunter syndrome are considered as can-
didate diseases, and the aim is to use this IVPRP approach to
facilitate the liver to produce in patients therapeutic quantities
of the normal enzymes, α-L-iduronidase and iduronate-2-sul-
fatase, respectively.
Non-viral vector systems such as sleeping beauty transpo-
son or phiC31 recombinase-derived vector represent other ap-
proaches for safe gene transfer in MPSs (Aronovich et al
2009; Stilhano et al 2015). However, the IDUA gene expres-
sion obtained with these methods decreases over time due to
the immune response and the metilation of the CAG promoter.
Further long-term clinical studies are needed to eval-
uate the therapeutic efficacy of gene therapy for MPS
patients.
It is also important to take into account that the clinical
efficacy of any innovative cellular and gene therapy procedure
is strictly dependent on providing the missing protein at a very
early stage, before symptoms become apparent. In future, ERT
should be envisaged in combined therapy with neonatal
HSCTor gene therapy for MPS patients soon after the neona-
tal diagnosis (Fig. 3). In fact, the combination of neonatal ERT
and delayed (5 weeks of age) BMT has already been per-
formed in a murine model of MPS VII with promising results
(Sands et al 1997).
To conclude, the perspective in the cure of MPSs should be
more focused not only on the use of combined treatments, but
also on the timing at which the therapies are given to patients,
considering that the clinical outcome could be more favorable
if the treatments are used to prevent instead of correcting the
disease manifestations.
Fig. 3 Potent ia l scheme of fu ture neona ta l the rapy for
mucopolysaccharidoses. Currently, ERT or HSCT are established
treatments and have a beneficial effect on patients with MPSs. In future,
neonatal cellular and gene therapy approaches combined with ERT could
be applied to affected children diagnosed at birth through the newborn
screening. Abbreviation: NBS, newborn screening; GAGs,
glycosaminoglycans; ERT, enzyme replacement therapy; HSCT,
hematopoietic stem cell transplantation
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